Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Inclusion Criteria:

• Female participants older than 18 years
• Documented evidence of cervical adenocarcinoma or squamous carcinoma FIGO StageIB2-IB3 node positive or Stage IIB-IVA
• No prior chemotherapy, immune checkpoint inhibitors or radiotherapy for cervicalcancer
• WHO/ECOG performance status of 0-1
• At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 TargetLesion at baseline.

Exclusion Criteria:

• Diagnosis of small cell (neuroendocrine) histology cervical cancer
• Intent to administer a fertility-sparing treatment regimen
• Undergone a previous hysterectomy
• Evidence of metastatic disease per RECIST 1.1 including lymph nodes ≥15 mm (shortaxis) above the L1 cephalad body or outside the planned radiation field.
• History of allogeneic organ transplantation
• Active or prior documented autoimmune or inflammatory disorders
• Uncontrolled intercurrent illness
• History of another primary malignancy and active primary immunodeficiency
• Patients with active infection Laboratory values that fall into:

1. WBC count (WBC) < 2000/μL ;
2. Neutrophil count < 1500/μL;
3. Platelet count < 100 x 103/μL;
4. Hemoglobin level < 9.0 g/dL;
5. Serum creatinine > 1.5 x upper limit of normal (ULN) unless creatinine clearance is ≥ 40 mL/min (measured or calculated using the Cockcroft-Gault formula);
6. Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT): > 3.0 x ULN;
7. Total bilirubin > 1.5 x ULN (except participants with Gilbert Syndrome who must have atotal bilirubin level of < 3.0 x ULN);
8. Any positive test result for hepatitis B virus or hepatitis C virus that indicates thepresence of the virus, for example, positive Hepatitis B surface antigen (HBsAg,Australia antigen) or Hepatitis C antibodies (anti- HCV) positive (unless the HCV-RNAis negative).

• Participants with a condition requiring systemic treatment or withcorticosteroids (>10 mg daily of a prednisone equivalent) or otherimmunosuppressive drugs within 14 days of initiating study treatment.
• Pregnant or breastfeeding woman